Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that, effective February 1, 2025, Nova Scotia is publicly funding Pluvictotm (lutetium (177Lu) vipivotide tetraxetan ...

Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that, effective 1, 2025, Nova Scotia is publicly funding Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan injection), providing ...

President Trump announced that the United States plans to impose additional tariffs on imports from Canada, China, and Mexico ...

During 2024, the radiopharmaceutical Pluvicto achieved blockbuster status, while sales of the breast cancer drug Kisqali grew 46 percent compared to 2023.

The poster titled “ Preclinical and Translational Pharmacokinetics of GD2-SADA, a Self-Assembling and Disassembling (SADA) Bispecific Fusion Protein for Pretargeted Radioimmunotherapy (PRIT)” ...

ITM announces positive Phase 3 results for ITM-11 in neuroendocrine tumours, paving the way for a potential new treatment ...

ORLANDO, FL / / January 31, 2025 / RedChip Companies will air interviews with Venu Holding Corporation ('VENU') (NYSE American:VENU) and ASP Isotopes (Nasdaq:ASPI) on the RedChip Small Stocks, Big ...

ONTARIO—The Ontario government is connecting more people to care by being the first Canadian jurisdiction to publicly fund and administer PLUVICTO, a new treatment for advanced-stage prostate cancer, ...

ITM's lutetium-containing therapy extended progression-free survival versus everolimus in patients with a specific kind of ...

ITM-11 beats everolimus in Phase 3 GEP-NETs trial; ITM plans filing. Drug will compete with Novartis's Lutathera. Both use ...

Discover ITM and its cancer candidate ITM-11 as it brings one of the first big wins the radiopharmaceutical sector awaits.

After 20 years of building radioisotope expertise as a manufacturer and supplier, German firm ITM Isotope Technologies is ...